According to Centers for Medicare & Medicaid Services, prescription drug spending is projected to grow at an average rate of 6.3% per year through 2025. Given this, I've been looking to pick up attractive pharmaceutical stocks. I recently came across Celgene (NASDAQ:CELG), which I recommend buying based on their attractive growth profile and de-risked clinical portfolio. It's rare to find a pharmaceutical company of Celgene's size ($94 billion market cap) with rocket-ship growth potential. I believe Celgene is on its way to becoming the next dominant pharma company. In a recent press release, Celgene reaffirmed their growth targets for 2020:
